| Recruiting | Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea NCT06952517 | Narrows Institute for Biomedical Research | Phase 2 |
| Withdrawn | Deucravacitinib Rosacea NCT06532136 | Icahn School of Medicine at Mount Sinai | Phase 2 |
| Withdrawn | Study to Evaluate the Safety of ATR-04 NCT04731259 | Azitra Inc. | Phase 1 / Phase 2 |
| Terminated | PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea NCT06013371 | Icahn School of Medicine at Mount Sinai | Phase 2 |
| Completed | Study of TP-04 in Participants With Papulopustular Rosacea NCT05838170 | Tarsus Pharmaceuticals, Inc. | Phase 2 |
| Completed | A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea ( NCT05343455 | Journey Medical Corporation | Phase 3 |
| Completed | A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for t NCT05296629 | Journey Medical Corporation | Phase 3 |
| Completed | Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea NCT05150587 | Alfasigma S.p.A. | Phase 2 |
| Withdrawn | A Safety and Efficacy Study to Evaluate Rosacea NCT03883945 | AiViva BioPharma, Inc. | Phase 1 / Phase 2 |
| Completed | Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties NCT05675501 | Sol-Gel Technologies, Ltd. | Phase 1 |
| Unknown | Topical Minocycline Gel for Inflammatory Lesions of Papulopustular Rosacea NCT03667222 | BioPharmX, Inc. | Phase 2 |
| Terminated | A Long-Term Safety Study of S5G4T-1 in the Treatment of Papulopustular Rosacea NCT03564145 | Sol-Gel Technologies, Ltd. | Phase 3 |
| Unknown | Safety and Efficacy of Rifaximin in Patients With Papulopustular Rosacea and Positive Lactulose Breath Test NCT03864978 | Alfasigma S.p.A. | Phase 2 |
| Completed | A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea NCT03564119 | Sol-Gel Technologies, Ltd. | Phase 3 |
| Completed | A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea NCT03448939 | Sol-Gel Technologies, Ltd. | Phase 3 |
| Completed | Study to Evaluate the Safety and Efficacy of Topical Minocycline Gel in Patients With Papulopustular Rosacea NCT03263273 | Hovione Scientia Limited | Phase 2 |
| Completed | A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to S NCT03276936 | Vyne Therapeutics Inc. | Phase 3 |
| Completed | Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea NCT03079531 | Anne Chang | Phase 1 / Phase 2 |
| Completed | Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular Rosacea NCT02601963 | Vyne Therapeutics Inc. | Phase 2 |
| Completed | A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea NCT02393937 | bioRASI, LLC | Phase 3 |
| Completed | Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea NCT02268474 | Cutera Inc. | N/A |
| Completed | Photodynamic Therapy for Papulopustular Rosacea NCT02075671 | George Washington University | Phase 4 |
| Completed | A 21 Day Pharmacokinetics Study in Papulopustular Rosacea NCT02028286 | Maruho Co., Ltd. | Phase 1 |
| Completed | An Analysis of the Effect of Topical Cromolyn Sodium on Rosacea-associated Erythema NCT01933464 | University of California, San Diego | Phase 1 / Phase 2 |
| Completed | Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea NCT01872715 | Galderma R&D | Phase 4 |
| Completed | A Twelve Week Safety and Efficacy Study in Rosacea NCT01784133 | Maruho Co., Ltd. | Phase 2 |
| Completed | Study to Evaluate the Efficacy and Safety of PAC-14028 Cream in Rosacea Patients NCT02052999 | Amorepacific Corporation | Phase 2 |
| Completed | Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea NCT01555463 | LEO Pharma | Phase 3 |
| Completed | CD5024 1% [Ivermectin 1%] Cream Versus Metronidazole 0.75% Cream in Papulopustular Rosacea (PPR) Study NCT01493947 | Galderma R&D | Phase 3 |
| Completed | Phase 3 Papulopustular Rosacea Study NCT01494467 | Galderma R&D | Phase 3 |
| Completed | Safety and Pharmacokinetics of Azelaic Acid Foam, 15% in Papulopustular Rosacea NCT01257919 | LEO Pharma | Phase 1 |
| Completed | Open Label Pilot Study of Apremilast in Treatment of Rosacea NCT01045551 | Julian M. Mackay-Wiggan | Phase 2 |
| Completed | Safety and Efficacy of Azelaic Acid Foam, 15% in Papulopustular Rosacea NCT01025635 | LEO Pharma | Phase 2 |
| Completed | Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus NCT00855595 | LEO Pharma | Phase 4 |
| Completed | Exploration of Safety and Efficacy of AzA 15% Foam Twice a Day in Rosacea NCT00617903 | LEO Pharma | Phase 2 |
| Completed | A Multicenter Trial of a Topical Medication for Papulopustular Rosacea Applied Twice Daily Versus Once Daily NCT00417937 | LEO Pharma | Phase 4 |